Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

453

Participants

Timeline

Start Date

May 29, 2020

Primary Completion Date

August 21, 2023

Study Completion Date

October 31, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Tislelizumab

administered via Intravenous (IV) injection

DRUG

Cisplatin injection

administered via IV infusion

DRUG

Paclitaxel injection

administered via IV infusion

DRUG

Pemetrexed Disodium

administered via IV infusion

DRUG

Placebos

Placebo to match tislelizumab IV infusion

DRUG

Carboplatin

administered via IV infusion

Trial Locations (44)

100044

Peking University Peoples Hospital, Beijing

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

100053

Xuanwu Hospital Capital Medical University, Beijing

100142

Beijing Cancer Hospital, Beijing

100730

Beijing Hospital, Beijing

Peking Union Medical College Hospital, Beijing

110042

Liaoning Cancer Hospital and Institute, Shenyang

130021

Jilin Cancer Hospital, Changchun

The First Hospital of Jilin University, Changchun

150000

Harbin Medical University Cancer Hospital, Harbin

200000

Fudan University Shanghai Cancer Center, Shanghai

200030

Shanghai Chest Hospital, Shanghai

200032

Affiliated Zhongshan Hospital of Fudan University, Shanghai

200433

Shanghai Pulmonary Hospital, Shanghai

210008

Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing

230000

Anhui Provincial Hospital, Hefei

300052

Tianjin Medical University General Hospital, Tianjin

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

310009

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

315000

Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo

330006

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

332000

The First Affiliated Hospital of Nanchang University Branch Xianghu, Nanchang

350001

Fujian Medical University Union Hospital, Fuzhou

350014

Fujian Cancer Hospital, Fuzhou

361003

The First Affiliated Hospital of Xiamen University, Xiamen

362000

Quanzhou First Affliated Hospital of Fujian Medical University, Quanzhou

410013

Hunan Cancer Hospital, Changsha

430022

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

430079

Hubei Cancer Hospital, Wuhan

471009

Luoyang Central Hospital, Luoyang

510030

Cancer Center of Guangzhou Medical University, Guangzhou

510060

Sun Yat Sen University Cancer Center, Guangzhou

515031

Cancer Hospital of Shantou University Medical College, Shantou

529030

Jiangmen Central Hospital, Jiangmen

530021

The Tumor Hospital Affiliated to Guangxi Medical University, Nanning

570312

Hainan Cancer Hospital, Haikou

610041

Sichuan Cancer Hospital and Institute, Chengdu

West China Hospital, Sichuan University, Chengdu

650100

Yunnan Cancer Hospital, Kunming

710061

The First Affiliated Hospital of Xian Jiaotong University, Xi'an

750004

General Hospital of Ningxia Medical University, Yinchuan

030000

First Hospital of Shanxi Medical University, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT04379635 - Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter